Paperpal Prime Logo

Breast Cancer: Targets and Therapy : Impact Factor & More

eISSN: 1179-1314pISSN: 1179-1314
JournalOpen Access

Key Metrics

CiteScore
5.9
Impact Factor
< 5
SJR
Q1Oncology
SNIP
1.51
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Breast Cancer: Targets and Therapy

Breast Cancer: Targets and Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher DOVE MEDICAL PRESS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2836
Publication Time16
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2009
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Breast Cancer: Targets and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Breast Cancer: Targets and Therapy

Exosomal miR-21 Derived from Paclitaxel-Resistant Breast Cancer Cells Promotes Chemoresistance in Breast Cancer via p53/PI3K/AKT/mTOR Signaling
  • 27 Jul 2026
  • Breast Cancer : Targets and Therapy
Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer
  • 24 Jul 2026
  • Breast Cancer : Targets and Therapy
Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer
  • 24 Jul 2026
  • Breast Cancer : Targets and Therapy
Suppressing M2 Macrophage Polarization by Glycine Combined with \u03b2-Elemene via the IL-6/JAK2/STAT3 Signaling Pathway to Inhibit Triple-Negative Breast Cancer Progression
  • 22 Jul 2026
  • Breast Cancer : Targets and Therapy
Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study
  • 15 Jul 2026
  • Breast Cancer : Targets and Therapy
Lipid Metabolic Reprogramming in Breast Cancer: Mechanisms and Emerging Therapeutic Strategies
  • 14 Jul 2026
  • Breast Cancer : Targets and Therapy
Exosomal miR-21 Derived from Paclitaxel-Resistant Breast Cancer Cells Promotes Chemoresistance in Breast Cancer via p53/PI3K/AKT/mTOR Signaling
  • 27 Jul 2026
  • Breast Cancer : Targets and Therapy
Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer
  • 24 Jul 2026
  • Breast Cancer : Targets and Therapy
Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer
  • 24 Jul 2026
  • Breast Cancer : Targets and Therapy
Suppressing M2 Macrophage Polarization by Glycine Combined with \u03b2-Elemene via the IL-6/JAK2/STAT3 Signaling Pathway to Inhibit Triple-Negative Breast Cancer Progression
  • 22 Jul 2026
  • Breast Cancer : Targets and Therapy
Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study
  • 15 Jul 2026
  • Breast Cancer : Targets and Therapy
Lipid Metabolic Reprogramming in Breast Cancer: Mechanisms and Emerging Therapeutic Strategies
  • 14 Jul 2026
  • Breast Cancer : Targets and Therapy

FAQs on Breast Cancer: Targets and Therapy